BMS achieves FDA approval for schizophrenia drug Cobenfy
Cobenfy (KarXT) is the first completely new type of schizophrenia drug to be approved for more than 30 years.
Archives for October 1, 2024
Self-amplifying mRNA COVID-19 vaccine shows superiority over conventional mRNA vaccine
A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a much lower dose.